Objective

The participant will:

Content

• Identify the key to successful hemostasis.
• Compare coagulation models.
• List phases of the cell-based model of coagulation.
• Name the coagulation factor that forms D-dimers and other fibrin degradation products.

Normal Hemostasis

• Specify what initiates the coagulation process.
• Identify the possible coagulation factors that may be involved when certain PT and aPTT results are found.
• Match the TEG and ROTEM parameters with their corresponding descriptions.

Investigation of Abnormal Hemostasis

• List laboratory findings typical of patients with hemophilia A.
• Indicate why recombinant preparations are preferred for the treatment of hemophilia A.
• State the role of antifibrinolytics in the treatment of hemophilia A.
• Characterize hemophilia B.
• Identify the use for the Nijmegen-modified Bethesda inhibitor assay.
• List the three most important screening assays for von Willebrand disease (vWD).
• Name the vWD variant that causes a severe hemophilia-like disease.

Inherited Hemostatic Defects

• Specify the cause of disseminated intravascular coagulation (DIC).
• Distinguish between overt and non-overt DIC.
• Identify the main triggering mechanism of DIC.
• Describe the most important aspect of managing patients with DIC.
• Name the disorder associated with the “lethal triad.”
• Specify the laboratory test usually used to guide perioperative or periprocedural plasma therapy.
• Identify the reason for most hemostatic defects found in uremic patients.
• Identify how excessive coagulation with warfarin is managed.
• Name the substance/condition monitored by the ecarin clotting time chromogenic assay.

Acquired Hemostatic Defects